Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Epigenomics AG (EPGNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: -0.047x
Based on the latest financial reports, Epigenomics AG (EPGNF) has a cash flow conversion efficiency ratio of -0.047x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($374.00K) by net assets ($-8.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Epigenomics AG - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Epigenomics AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Epigenomics AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epigenomics AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BEACN Wizardry & Magic Inc
V:BECN
|
-1.349x |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
0.889x |
|
Bowler Metcalf Ltd
JSE:BCF
|
0.092x |
|
JPMorgan Equity And Options Total Return ETF
BATS:JOYT
|
N/A |
|
Xali Gold Corp
PINK:CGDXF
|
0.030x |
|
NGS Group AB (publ)
ST:NGS
|
-0.036x |
|
BRIT AMER TOBACCO - Dusseldorf Stock Exchang
DU:BMT
|
N/A |
|
MAGNA INTL - Dusseldorf Stock Exchang
DU:MGA
|
0.057x |
Annual Cash Flow Conversion Efficiency for Epigenomics AG (2003–2024)
The table below shows the annual cash flow conversion efficiency of Epigenomics AG from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-11.24 Million | $-1.20 Million | 0.107x | -84.98% |
| 2023-12-31 | $-8.02 Million | $-5.71 Million | 0.712x | +160.27% |
| 2022-12-31 | $10.17 Million | $-12.02 Million | -1.182x | -529.75% |
| 2021-12-31 | $22.12 Million | $-4.15 Million | -0.188x | +92.42% |
| 2020-12-31 | $3.86 Million | $-9.57 Million | -2.477x | -76.59% |
| 2019-12-31 | $9.63 Million | $-13.51 Million | -1.403x | -152.22% |
| 2018-12-31 | $18.61 Million | $-10.35 Million | -0.556x | +38.58% |
| 2017-12-31 | $10.58 Million | $-9.58 Million | -0.905x | +1.69% |
| 2016-12-31 | $14.42 Million | $-13.28 Million | -0.921x | +19.57% |
| 2015-12-31 | $7.10 Million | $-8.13 Million | -1.145x | +3.15% |
| 2014-12-31 | $6.11 Million | $-7.22 Million | -1.182x | -17.39% |
| 2013-12-31 | $6.46 Million | $-6.50 Million | -1.007x | +61.53% |
| 2012-12-31 | $4.16 Million | $-10.88 Million | -2.618x | -365.03% |
| 2011-12-31 | $16.19 Million | $-9.11 Million | -0.563x | -85.84% |
| 2010-12-31 | $31.30 Million | $-9.48 Million | -0.303x | +65.56% |
| 2009-12-31 | $12.08 Million | $-10.63 Million | -0.880x | -48.71% |
| 2008-12-31 | $16.57 Million | $-9.80 Million | -0.592x | +6.25% |
| 2007-12-31 | $17.82 Million | $-11.24 Million | -0.631x | -25.50% |
| 2006-12-31 | $28.46 Million | $-14.31 Million | -0.503x | -363.90% |
| 2005-12-31 | $39.38 Million | $7.50 Million | 0.191x | +2.36% |
| 2004-12-31 | $47.74 Million | $8.88 Million | 0.186x | -47.99% |
| 2003-12-31 | $17.71 Million | $6.34 Million | 0.358x | -- |